{"classes":[{"categories":[{"measurements":[{"comment":"Data for upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"36.6","upperLimit":"NA","value":"60.4"},{"comment":"Data for median and upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"13.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. Definitions for CR, PR are defined in OM#1. PD is defined in OM#6.\n\nKM estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEDIAN","populationDescription":"Participants with OR in Full Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"DOR by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"months"}